Home » Stocks » AVCO

Avalon GloboCare Corp. (AVCO)

Stock Price: $0.940 USD 0.033 (3.66%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $0.940 0.000 (-0.02%) May 13, 5:30 PM
Market Cap 77.65M
Revenue (ttm) 1.38M
Net Income (ttm) -12.68M
Shares Out 84.41M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $0.940
Previous Close $0.907
Change ($) 0.033
Change (%) 3.66%
Day's Open 0.906
Day's Range 0.900 - 0.950
Day's Volume 241,298
52-Week Range 0.870 - 2.160

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Specializes in developing cell-based technologies and manages stem-cell banks and clinical laboratories Creates proprietary diagnostic and therapeutic products leveraging regenerative medicine and exoso...

3 weeks ago - Proactive Investors

Avalon GloboCare Corp (NASDAQ:AVCO) said it will collaborate with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the company's AVA-011 therapy and other RNA-based ca...

1 month ago - Proactive Investors

FREEHOLD, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today ann...

1 month ago - GlobeNewsWire

Avalon GloboCare Corp (NASDAQ:AVCO) has said it is expanding its co-development research program with the Massachusetts Institute of Technology (MIT), involving the use of CRISPR-based genome editing an...

1 month ago - Proactive Investors

FREEHOLD, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today ann...

1 month ago - GlobeNewsWire

Specializes in developing cell-based technologies and manages stem-cell banks and clinical laboratories Creates proprietary diagnostic and therapeutic products leveraging regenerative medicine and exoso...

1 month ago - Proactive Investors

FREEHOLD, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today anno...

4 months ago - GlobeNewsWire

Assure/Fastep® COVID-19 Point-of-Care Antibody Test is the First Test Granted FDA Emergency Use Authorization for Use with Fingerstick Blood Samples Assure/Fastep® COVID-19 Point-of-Care Antibody Test i...

6 months ago - GlobeNewsWire

FREEHOLD, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a clinical update o...

7 months ago - GlobeNewsWire

FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today a...

8 months ago - GlobeNewsWire

FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today a...

8 months ago - GlobeNewsWire

In anticipation of high demand, Avalon is working with Cellex to source manufacturing facilities and develop next generation COVID-19 testing kits In anticipation of high demand, Avalon is working with ...

8 months ago - GlobeNewsWire

FREEHOLD, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announce...

9 months ago - GlobeNewsWire

FREEHOLD, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced an update on its...

10 months ago - GlobeNewsWire

- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

10 months ago - GlobeNewsWire

- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel S-layer ...

10 months ago - GlobeNewsWire

FREEHOLD, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that the Company...

10 months ago - GlobeNewsWire

FREEDHOLD, N.J., June 08, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based therapeutics and in vitro diagnostics, announced today that th...

11 months ago - GlobeNewsWire

FREEHOLD, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has achie...

1 year ago - GlobeNewsWire

FREEHOLD, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has for...

1 year ago - GlobeNewsWire

FREEHOLD, N.J., April 20, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has ach...

1 year ago - GlobeNewsWire

FREEHOLD, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it will pre...

1 year ago - GlobeNewsWire

FREEHOLD, N.J., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has establish...

1 year ago - GlobeNewsWire

Avalon: Fortressing Capital Structure And Strengthening Fundamentals

1 year ago - Seeking Alpha

Company to Remain with Zero Warrants Outstanding Company to Remain with Zero Warrants Outstanding

1 year ago - GlobeNewsWire

Avalon's CAR-Ts are ahead of their time due to key advantages over conventional medicines. AVA-101 shuttles enough genes to decimate two oncology targets (CD19 and CD22).

1 year ago - Seeking Alpha

Unsecured credit facility carries 5% interest, all payments deferred for 36 months and is non-convertible into equity; Proceeds to be used to accelerate R&D, clinical studies and commercialization progr...

1 year ago - GlobeNewsWire

Avalon is gearing to hit a trifecta with three highly promising businesses, including exosome diagnostics, regenerative medicine, and cellular immunotherapy.

Other stocks mentioned: GE
1 year ago - Seeking Alpha

Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters.

1 year ago - Seeking Alpha

About AVCO

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, c... [Read more...]

Industry
Medical Care Facilities
Stock Exchange
NASDAQ
Ticker Symbol
AVCO
Full Company Profile

Financial Performance

In 2020, AVCO's revenue was $1.38 million, a decrease of -10.90% compared to the previous year's $1.55 million. Losses were -$12.68 million, -29.83% less than in 2019.

Financial Statements